The antibiotic Factive, also known as gemifloxacin, used to treat acute sinus infections has been linked to serious skin reactions, according to the Food and Drug Administration (FDA). Compared to similar antibiotics, the risk of rashes associated with Factive is greater
The FDA plans to ask members of its anti-infective drugs advisory committee if the antibiotic’s benefits outweigh its risks. If the FDA advisory panel does not support the drug, the FDA will determine whether more study is needed. Factive gained FDA approval in 2003 as a treatment for pneumonia and acute bronchitis.